Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21286842 | 1.00 | LMNA (0.38) | LMNAMAPK1L3MBTL1ALDH1A1GAA | |
| SCHEMBL21916186 | 1.00 | LMNA (0.38) | LMNAMAPK1L3MBTL1ALDH1A1GAA | |
| SCHEMBL20997322 | 1.00 | LMNA (0.38) | LMNAMAPK1L3MBTL1ALDH1A1GAA | |
| SCHEMBL21286816 | 0.86 | KMT2A (0.39) | MAPK1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL21625351 | 0.86 | KMT2A (0.39) | MAPK1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL21625352 | 0.86 | KMT2A (0.39) | MAPK1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL20997082 | 0.86 | KMT2A (0.39) | MAPK1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL21915010 | 0.86 | KMT2A (0.39) | MAPK1ALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL24250654 | 0.82 | KMT2A (0.38) | GAAKMT2A | |
| SCHEMBL21915155 | 0.82 | KMT2A (0.38) | GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10538502-B2 | Tricyclic spiro compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2020-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10538502-B2 | Tricyclic spiro compound | PTGER4, PTGER1, PTGER3 | LMNA 1857/4885MAPK1 1698/4885L3MBTL1 3780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.